Shopping Cart 0
Cart Subtotal
USD 0

Biotechnology in Japan

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Single User License
USD 350

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Site License
USD 700

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Deliverable Format : Excel, PDF Via Email

Corporate User License
USD 1050
  • Details
  • Table Of Content
  • Licence Rights
  • Section Purchase

Details

Biotechnology in Japan

Summary

Biotechnology in Japan industry profile provides top-line qualitative and quantitative summary information including: market size (value 2013-17, and forecast to 2022). The profile also contains descriptions of the leading players including key financial metrics and analysis of competitive pressures within the market.

Synopsis

Essential resource for top-line data and analysis covering the Japan biotechnology market. Includes market size and segmentation data, textual and graphical analysis of market growth trends, leading companies and macroeconomic information.

Key highlights

- The biotechnology market consists of the development, manufacturing, and marketing of products based on advanced biotechnology research.

- The Japanese biotechnology industry had total revenues of USD 35.8bn in 2017, representing a compound annual growth rate (CAGR) of 3% between 2013 and 2017.

- The environment and industrial processing segment was the industry's most lucrative in 2017, with total revenues of USD 13.9bn, equivalent to 38.9% of the industry's overall value.

- The country has set a range of environmental targets, including an emissions reduction target of 26% below 2013 levels by 2030. Investment in biotechnology is expected to help the country reach these targets.

Scope

- Save time carrying out entry-level research by identifying the size, growth, major segments, and leading players in the biotechnology market in Japan

- Use the Five Forces analysis to determine the competitive intensity and therefore attractiveness of the biotechnology market in Japan

- Leading company profiles reveal details of key biotechnology market players' global operations and financial performance

- Add weight to presentations and pitches by understanding the future growth prospects of the Japan biotechnology market with five year forecasts

Reasons to buy

- What was the size of the Japan biotechnology market by value in 2017?

- What will be the size of the Japan biotechnology market in 2022?

- What factors are affecting the strength of competition in the Japan biotechnology market?

- How has the market performed over the last five years?

- What are the main segments that make up Japan's biotechnology market?

READ MORE

Table Of Content

Scope

Table of Contents

Executive Summary 2

Market value 2

Market value forecast 2

Category segmentation 2

Geography segmentation 2

Market rivalry 2

Market Overview 7

Market definition 7

Market analysis 7

Market Data 8

Market value 8

Market Segmentation 9

Category segmentation 9

Geography segmentation 10

Market Outlook 11

Market value forecast 11

Five Forces Analysis 12

Summary 12

Buyer power 13

Supplier power 14

New entrants 15

Threat of substitutes 17

Degree of rivalry 18

Leading Companies 19

Astellas Pharma Inc. 19

Daiichi Sankyo Co., Ltd. 22

Mitsubishi Tanabe Pharma Corporation 25

Takeda Pharmaceutical Company Limited 28

Macroeconomic Indicators 31

Country data 31

Methodology 33

Industry associations 34

Related MarketLine research 34

Appendix 35

About MarketLine 35


List Of Figure

List of Figures

Figure 1: Japan biotechnology industry value: USD billion, 2013-17

Figure 2: Japan biotechnology industry category segmentation: % share, by value, 2017

Figure 3: Japan biotechnology industry geography segmentation: % share, by value, 2017

Figure 4: Japan biotechnology industry value forecast: USD billion, 2017-22

Figure 5: Forces driving competition in the biotechnology industry in Japan, 2017

Figure 6: Drivers of buyer power in the biotechnology industry in Japan, 2017

Figure 7: Drivers of supplier power in the biotechnology industry in Japan, 2017

Figure 8: Factors influencing the likelihood of new entrants in the biotechnology industry in Japan, 2017

Figure 9: Factors influencing the threat of substitutes in the biotechnology industry in Japan, 2017

Figure 10: Drivers of degree of rivalry in the biotechnology industry in Japan, 2017

Figure 11: Astellas Pharma Inc.: revenues & profitability

Figure 12: Astellas Pharma Inc.: assets & liabilities

Figure 13: Daiichi Sankyo Co., Ltd.: revenues & profitability

Figure 14: Daiichi Sankyo Co., Ltd.: assets & liabilities

Figure 15: Mitsubishi Tanabe Pharma Corporation: revenues & profitability

Figure 16: Mitsubishi Tanabe Pharma Corporation: assets & liabilities

Figure 17: Takeda Pharmaceutical Company Limited: revenues & profitability

Figure 18: Takeda Pharmaceutical Company Limited: assets & liabilities


List Of Table

List of Tables

Table 1: Japan biotechnology industry value: USD billion, 2013-17

Table 2: Japan biotechnology industry category segmentation: USD billion, 2017

Table 3: Japan biotechnology industry geography segmentation: USD billion, 2017

Table 4: Japan biotechnology industry value forecast: USD billion, 2017-22

Table 5: Astellas Pharma Inc.: key facts

Table 6: Astellas Pharma Inc.: key financials (USD )

Table 7: Astellas Pharma Inc.: key financials (JPY)

Table 8: Astellas Pharma Inc.: key financial ratios

Table 9: Daiichi Sankyo Co., Ltd.: key facts

Table 10: Daiichi Sankyo Co., Ltd.: key financials (USD )

Table 11: Daiichi Sankyo Co., Ltd.: key financials (JPY)

Table 12: Daiichi Sankyo Co., Ltd.: key financial ratios

Table 13: Mitsubishi Tanabe Pharma Corporation: key facts

Table 14: Mitsubishi Tanabe Pharma Corporation: key financials (USD )

Table 15: Mitsubishi Tanabe Pharma Corporation: key financials (JPY)

Table 16: Mitsubishi Tanabe Pharma Corporation: key financial ratios

Table 17: Takeda Pharmaceutical Company Limited: key facts

Table 18: Takeda Pharmaceutical Company Limited: key financials (USD )

Table 19: Takeda Pharmaceutical Company Limited: key financials (JPY)

Table 20: Takeda Pharmaceutical Company Limited: key financial ratios

Table 21: Japan size of population (million), 2013-17

Table 22: Japan gdp (constant 2005 prices, USD billion), 2013-17

Table 23: Japan gdp (current prices, USD billion), 2013-17

Table 24: Japan inflation, 2013-17

Table 25: Japan consumer price index (absolute), 2013-17

Table 26: Japan exchange rate, 2013-17

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License: 
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:  
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

Biotechnology in Japan

Summary

Biotechnology in Japan industry profile provides top-line qualitative and quantitative summary information including: market size (value 2013-17, and forecast to 2022). The profile also contains descriptions of the leading players including key financial metrics and analysis of competitive pressures within the market.

Synopsis

Essential resource for top-line data and analysis covering the Japan biotechnology market. Includes market size and segmentation data, textual and graphical analysis of market growth trends, leading companies and macroeconomic information.

Key highlights

- The biotechnology market consists of the development, manufacturing, and marketing of products based on advanced biotechnology research.

- The Japanese biotechnology industry had total revenues of USD 35.8bn in 2017, representing a compound annual growth rate (CAGR) of 3% between 2013 and 2017.

- The environment and industrial processing segment was the industry's most lucrative in 2017, with total revenues of USD 13.9bn, equivalent to 38.9% of the industry's overall value.

- The country has set a range of environmental targets, including an emissions reduction target of 26% below 2013 levels by 2030. Investment in biotechnology is expected to help the country reach these targets.

Scope

- Save time carrying out entry-level research by identifying the size, growth, major segments, and leading players in the biotechnology market in Japan

- Use the Five Forces analysis to determine the competitive intensity and therefore attractiveness of the biotechnology market in Japan

- Leading company profiles reveal details of key biotechnology market players' global operations and financial performance

- Add weight to presentations and pitches by understanding the future growth prospects of the Japan biotechnology market with five year forecasts

Reasons to buy

- What was the size of the Japan biotechnology market by value in 2017?

- What will be the size of the Japan biotechnology market in 2022?

- What factors are affecting the strength of competition in the Japan biotechnology market?

- How has the market performed over the last five years?

- What are the main segments that make up Japan's biotechnology market?

READ MORE

Scope

Table of Contents

Executive Summary 2

Market value 2

Market value forecast 2

Category segmentation 2

Geography segmentation 2

Market rivalry 2

Market Overview 7

Market definition 7

Market analysis 7

Market Data 8

Market value 8

Market Segmentation 9

Category segmentation 9

Geography segmentation 10

Market Outlook 11

Market value forecast 11

Five Forces Analysis 12

Summary 12

Buyer power 13

Supplier power 14

New entrants 15

Threat of substitutes 17

Degree of rivalry 18

Leading Companies 19

Astellas Pharma Inc. 19

Daiichi Sankyo Co., Ltd. 22

Mitsubishi Tanabe Pharma Corporation 25

Takeda Pharmaceutical Company Limited 28

Macroeconomic Indicators 31

Country data 31

Methodology 33

Industry associations 34

Related MarketLine research 34

Appendix 35

About MarketLine 35


List Of Figure

List of Figures

Figure 1: Japan biotechnology industry value: USD billion, 2013-17

Figure 2: Japan biotechnology industry category segmentation: % share, by value, 2017

Figure 3: Japan biotechnology industry geography segmentation: % share, by value, 2017

Figure 4: Japan biotechnology industry value forecast: USD billion, 2017-22

Figure 5: Forces driving competition in the biotechnology industry in Japan, 2017

Figure 6: Drivers of buyer power in the biotechnology industry in Japan, 2017

Figure 7: Drivers of supplier power in the biotechnology industry in Japan, 2017

Figure 8: Factors influencing the likelihood of new entrants in the biotechnology industry in Japan, 2017

Figure 9: Factors influencing the threat of substitutes in the biotechnology industry in Japan, 2017

Figure 10: Drivers of degree of rivalry in the biotechnology industry in Japan, 2017

Figure 11: Astellas Pharma Inc.: revenues & profitability

Figure 12: Astellas Pharma Inc.: assets & liabilities

Figure 13: Daiichi Sankyo Co., Ltd.: revenues & profitability

Figure 14: Daiichi Sankyo Co., Ltd.: assets & liabilities

Figure 15: Mitsubishi Tanabe Pharma Corporation: revenues & profitability

Figure 16: Mitsubishi Tanabe Pharma Corporation: assets & liabilities

Figure 17: Takeda Pharmaceutical Company Limited: revenues & profitability

Figure 18: Takeda Pharmaceutical Company Limited: assets & liabilities


List Of Table

List of Tables

Table 1: Japan biotechnology industry value: USD billion, 2013-17

Table 2: Japan biotechnology industry category segmentation: USD billion, 2017

Table 3: Japan biotechnology industry geography segmentation: USD billion, 2017

Table 4: Japan biotechnology industry value forecast: USD billion, 2017-22

Table 5: Astellas Pharma Inc.: key facts

Table 6: Astellas Pharma Inc.: key financials (USD )

Table 7: Astellas Pharma Inc.: key financials (JPY)

Table 8: Astellas Pharma Inc.: key financial ratios

Table 9: Daiichi Sankyo Co., Ltd.: key facts

Table 10: Daiichi Sankyo Co., Ltd.: key financials (USD )

Table 11: Daiichi Sankyo Co., Ltd.: key financials (JPY)

Table 12: Daiichi Sankyo Co., Ltd.: key financial ratios

Table 13: Mitsubishi Tanabe Pharma Corporation: key facts

Table 14: Mitsubishi Tanabe Pharma Corporation: key financials (USD )

Table 15: Mitsubishi Tanabe Pharma Corporation: key financials (JPY)

Table 16: Mitsubishi Tanabe Pharma Corporation: key financial ratios

Table 17: Takeda Pharmaceutical Company Limited: key facts

Table 18: Takeda Pharmaceutical Company Limited: key financials (USD )

Table 19: Takeda Pharmaceutical Company Limited: key financials (JPY)

Table 20: Takeda Pharmaceutical Company Limited: key financial ratios

Table 21: Japan size of population (million), 2013-17

Table 22: Japan gdp (constant 2005 prices, USD billion), 2013-17

Table 23: Japan gdp (current prices, USD billion), 2013-17

Table 24: Japan inflation, 2013-17

Table 25: Japan consumer price index (absolute), 2013-17

Table 26: Japan exchange rate, 2013-17

Single User License:
Report can be used by individual purchaser only

Site License: 
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:  
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to support@kenresearch.com